143 related articles for article (PubMed ID: 7951008)
1. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Bennett CL; Oddone E; Matchar D
Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
[TBL] [Abstract][Full Text] [Related]
4. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
Schulman KA; Dorsainvil D; Yabroff KR; DiCesare J; Felser J; Eisenberg JM; Glick HA
Bone Marrow Transplant; 1998 Mar; 21(6):607-14. PubMed ID: 9543065
[TBL] [Abstract][Full Text] [Related]
5. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation.
Barge AJ
Bone Marrow Transplant; 1993; 11 Suppl 2():1-11. PubMed ID: 8334433
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of colony stimulating factors for established neutropenic fever.
Walton SM
W V Med J; 1998; 94(1):26-8. PubMed ID: 9505567
[TBL] [Abstract][Full Text] [Related]
8. The role of cytokines following bone marrow transplantation: indications and controversies.
Weinthal JA
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S10-4. PubMed ID: 8971400
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care.
Uyl-de Groot CA
Eur J Cancer; 2006 Nov; 42(17):2862-6. PubMed ID: 17008095
[TBL] [Abstract][Full Text] [Related]
10. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
11. GM-CSF as an adjunct to autologous bone marrow transplantation.
Gulati S; Bennett C; Phillips J; Van-Poznak C
Stem Cells; 1993 Jan; 11(1):20-5. PubMed ID: 8457776
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia.
Weber RJ
Clin Ther; 1993; 15(1):180-91; discussion 168. PubMed ID: 8458047
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
14. Cytokine therapy after bone marrow transplantation.
Dix SP; Gilmore CE
Pharmacotherapy; 1996; 16(4):593-608. PubMed ID: 8840365
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
[TBL] [Abstract][Full Text] [Related]
16. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
17. [Current status of the clinical application of hematopoietic growth factors in oncology].
Karthaus M; Ganser A
Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
[TBL] [Abstract][Full Text] [Related]
18. Growth factors in allogeneic transplantation.
Nemunaitis J
Semin Oncol; 1993 Oct; 20(5 Suppl 6):96-101. PubMed ID: 8211221
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
Anderson JE; Appelbaum FR
Curr Opin Hematol; 1994 May; 1(3):203-9. PubMed ID: 9371283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
